Susceptibility of twenty penicillin-susceptible and -resistant pneumococci to levofloxacin, ciprofloxacin, ofloxacin, erythromycin, azithromycin, and clarithromycin by MIC and time-kill

Appelbaum, 1992, Antimicrobial resistance in Streptococcus penumoniae—An overview, Clin Infect Dis, 15, 77, 10.1093/clinids/15.1.77 Baquero, 1991, A review of antibiotic resistance patterns of Streptococcus pneumoniae in Europe, J Antimicrob Chemother, 30, 9 Barry, 1996, In-vitro susceptibility of Streptococcus pneumoniae to the d- and I-isomers of ofloxacin: Interpretive criteria and quality control limits, J Antimicrob Chemother, 37, 365, 10.1093/jac/37.2.365 Block, 1995, Penicillin-resistant Streptococcus pneumoniae in acute otitis media: Risk factors, susceptibility patterns, and antimicrobial management, Pediat Infect Dis J, 14, 751, 10.1097/00006454-199509000-00005 Breiman, 1994, Emergence of drug-resistant pneumococcal infections in the United States, JAMA, 271, 1831, 10.1001/jama.271.23.1831 Child, 1995, Open-label cross-over study to determine pharmacokinetics and penetration of two dose regimens of levofloxacin into inflammatory fluid, Antimicrob Agents Chemother, 39, 2749, 10.1128/AAC.39.12.2749 Cormican, 1995, Susceptibility to levofloxacin predicted from in vitro susceptibility testing results obtained with ciprofloxacin and ofloxacin, Antimicrob Agents Chemother, 33, 215 Doern, 1996, Antimicrobial resistance of Streptococcus pneumoniae recovered from outpatients in the United States during the winter months of 1994 to 1995: Results of a 30-center national surveillance study, Antimicrob Agents Chemother, 40, 1208, 10.1128/AAC.40.5.1208 Friedland, 1992, Management of penicillin-resistant pneumococcal infections, Pediatr Infect Dis J, 11, 433, 10.1097/00006454-199206000-00002 Friedland, 1994, Management of infections caused by antibiotic-resistant Streptococcus penumoniae, N Engl J Med, 331, 377, 10.1056/NEJM199408113310607 Fu, 1992, In vitro and in vivo antibacterial activities of levofloxacin (I-ofloxacin), an optically active ofloxacin, Antimicrob Agents Chemother, 36, 860, 10.1128/AAC.36.4.860 Hofmann, 1995, The prevalence of drug resistant Streptococcus pneumoniae in Atlanta, N Engl J Med, 333, 481, 10.1056/NEJM199508243330803 Jacobs, 1992, Treatment and diagnosis of infections caused by drug-resistant Streptococcus pneumoniae, Clin Infect Dis, 15, 119, 10.1093/clinids/15.1.119 Jacobs, 1995, Antibiotic-resistant pneumococcci, Rev Med Microbiol, 6, 77, 10.1097/00013542-199504000-00001 Kam, 1995, Emergence of multiple antibiotic-resistant Streptococcus pneumoniae in Hong Kong, Antimicrob Agents Chemother, 39, 2667, 10.1128/AAC.39.12.2667 Klugman, 1990, Pneumococcal resistance to antibiotics, Clin Microbiol Rev, 3, 171, 10.1128/CMR.3.2.171 Mason, 1992, Increased rate of isolation of penicillin-resistant Streptococcus pneumoniae in a children's hospital and in vitro susceptibilities to antibiotics of potential therapeutic use, Antimicrob Agents Chemother, 36, 1703, 10.1128/AAC.36.8.1703 McDougal, 1992, Analysis of multiply antimicrobial-resistant isolates of Streptococcus pneumoniae from the United States, Antimicrob Agents Chemother, 36, 2176, 10.1128/AAC.36.10.2176 Munoz, 1992, Geographic distribution of penicillin-resistant clones of Streptococcus pneumoniae: Characterization by penicillin-binding protein profile, surface protein A typing, and multilocus enzyme analysis, Clin Infect Dis, 15, 112, 10.1093/clinids/15.1.112 National Committee for Clinical Laboratory Standards (NCCLS), 1997 Nelson, 1994, Activity of oral antibiotics in middle ear and sinus infections caused by penicillin-resistant Streptococcus pneumoniae: Implications for treatment, Pediatr Infect Dis J, 13, 585, 10.1097/00006454-199407000-00001 Neu, 1989, In vitro activity of S-ofloxacin, Antimicrob Agents Chemother, 33, 1105, 10.1128/AAC.33.7.1105 Pankuch, 1994, Study of comparative antipneumococcal activities of penicillin G, RP 59500, erythromycin, sparfloxacin, ciprofloxacin, and vancomycin by using time-kill methodology, Antimicrob Agents Chemother, 38, 2065, 10.1128/AAC.38.9.2065 Pankuch, 1995, Activity of CP 99,219 compared to DU-6859a, ciprofloxacin, ofloxacin, levofloxacin, lomefloxacin, tosufloxacin, sparfloxacin, and grepafloxacin against penicillin-susceptible and -resistant pneumococci, J Antimicrob Chemother, 35, 230, 10.1093/jac/35.1.230 Spangler, 1992, Susceptibilities of penicillin-susceptible and -resistant strains of Streptococcus pneumoniae to RP 59500, vancomycin, erythromycin, PD 131628, sparfloxacin, temafloxacin, Win 57273, ofloxacin, and ciprofloxacin, Antimicrob Agents Chemother, 36, 856, 10.1128/AAC.36.4.856 Spangler, 1993, Susceptibility of 170 penicillin-susceptible and -resistant pneumococci to six oral cephalosporins, four quinolones, desacetylcefotaxime, Ro 23-9424, and RP 67829, J Antimicrob Chemother, 31, 273, 10.1093/jac/31.2.273 Sutton, 1995, Suggested modifications for disk-diffusion susceptibility testing criteria for levofloxacin and sparfloxacin following tests with a predictor panel of ciprofloxacin-resistant clinical isolates, Antimicrob Agents Chemother, 33, 146 Visalli, 1996, MIC and time-kill study of activities of DU-6859a, ciprofloxacin, levofloxacin, sparfloxacin, cefotaxime, imipenem, and vancomycin against nine penicillin-susceptible and -resistant pneumococci, Antimicrob Agents Chemother, 40, 362, 10.1128/AAC.40.2.362